8-KOther Events

THERMO FISHER SCIENTIFIC INC. 8-K Report (Jul 28, 2004)

Filed July 28, 2004For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) filed this 8-K on July 28, 2004, to report its financial results for the second quarter ended July 3, 2004. The company announced a 12% increase in total revenues to $525 million, driven by both organic growth (3%) and the impact of acquisitions (6%). Diluted EPS on a GAAP basis was $0.54, significantly up from $0.32 in the prior year, aided by a tax benefit from discontinued operations. On an adjusted basis, which excludes certain items, EPS grew 7% to $0.29, and operating income increased 16%, with adjusted operating margin improving to 12.5% from 12.1% year-over-year. The report also highlights significant strategic moves. The company completed the acquisition of USCS, a laboratory services business, for $75 million and announced the sale of its Spectra-Physics business for $300 million (which closed after the quarter end). These divestitures signal a strategic focus on core segments: Life and Laboratory Sciences and Measurement and Control. The company reiterated its full-year adjusted EPS guidance of $1.20 to $1.25.

Key Highlights

  • 1Total revenues grew 12% year-over-year to $525 million for Q2 2004.
  • 2GAAP diluted EPS increased to $0.54 from $0.32 in the prior year, benefiting from a tax credit in discontinued operations.
  • 3Adjusted diluted EPS rose 7% to $0.29, meeting the top end of guidance.
  • 4Organic revenue growth was 3%, indicating underlying business expansion.
  • 5The company acquired USCS for $75 million, strengthening its laboratory services segment.
  • 6Thermo Fisher announced the sale of its Spectra-Physics business for $300 million, marking a strategic divestiture.
  • 7Full-year adjusted EPS guidance of $1.20 to $1.25 was reiterated.

Frequently Asked Questions

Thermo Fisher reported a 12% revenue increase to $525 million. This growth was a combination of 3% organic revenue growth, 3% from favorable currency translation, and 6% from acquisitions and divestitures.

On a GAAP basis, diluted EPS was $0.54, a significant increase from $0.32 in the prior year, partly due to a tax benefit from discontinued operations. Adjusted diluted EPS grew 7% to $0.29. Adjusted operating income increased 16% year-over-year, and the adjusted operating margin improved to 12.5% from 12.1%.

The company completed the acquisition of USCS for $75 million, enhancing its laboratory services business. Additionally, Thermo Fisher announced the sale of its Spectra-Physics business for $300 million. These actions indicate a strategic focus on its core Life and Laboratory Sciences and Measurement and Control segments.

Thermo Fisher reiterated its full-year adjusted EPS guidance of $1.20 to $1.25. The company also provided guidance for the third quarter of 2004, expecting adjusted EPS to be between $0.28 and $0.30.